SOURCE: CryoPort, Inc.

April 30, 2008 10:34 ET

Ludlow Bioventures Initiates Coverage on CryoPort

NEW YORK, NY--(Marketwire - April 30, 2008) - Ludlow BioVentures, Inc. has initiated research coverage on CryoPort Inc. (OTCBB: CYRX) based on the company's successful shipment of clinical samples on behalf of Quest Diagnostics.

SUMMARY

CryoPort's initial shipment of clinical samples for Quest Diagnostics demonstrates the viability of the company's One-Way Shipment System called CryoPort ExpressTM. This shipping system provides a total cold-chain global shipping solution for high quality, temperature sensitive clinical, lab or medical samples. The teamwork between CryoPort and Fedex ensures the reliability and integrity of clinical shipments.

This initial success demonstrates to Ludlow BioVentures that CryoPort has developed a shipping method that represents a complete end-to-end solution that provides more convenience for CryoPort's clients with less environmental impact. As a result CryoPort's One-Way Shipment System could prove to be a cost-effective, single-sourced cold chain shipping method.

With the successful shipment of clinical samples on behalf of Quest Diagnostics, Ludlow BioVentures has initiated research coverage on CYRX and is adding CYRX to our client watch list.

ABOUT CRYOPORT, INC

CryoPort develops leading edge, proprietary, technology-driven shipping and storage products for use in the rapidly growing global biotechnology and biopharmaceutical cold chain. The products developed by CryoPort are essential components of the infrastructure required for the testing, research and end user delivery of temperature-sensitive medicines and biomaterials in an increasingly complex logistical environment.

About Ludlow BioVentures, Inc

Based in New York City, Ludlow BioVenture is a venture capital and research advisory firm with a specific focus on the renewable and alternative energy markets. The goal of the firm is to promote investments into alternative and renewable energy projects and ventures worldwide. Ludlow BioVentures owns and operates the Ludlow BioVenture Index, which tracks a wide basket of US traded large and small cap biotechnology stocks. www.ludlowcapital.com

Disclosure: This is NOT a solicitation to Buy or Sell any security, but rather is for research purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Ludlow BioVentures does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. Ludlow BioVentures, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encourage to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Ludlow BioVentures was NOT compensated for the distribution of this research material, but may hold a position in the above securities in the Ludlow Biotech fund, and should thus be considered a possible conflict of interest when reviewing this report and information.

Disclaimer:

This is NOT a solicitation to Buy or Sell any security, but rather is for information purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Ludlow Capital does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse, these views, opinions or recommendations, give investment advice. Ludlow Capital, its affiliates, or directors, may possibly hold a position in the above security from time to time, and investors are encourage to consider this as a possible conflict of interest when review this information. In Compliance with SEC Rule 17B, Ludlow Capital was NOT compensated for adding this news alert to our website.

"SAFE HARBOR"

This press release contains forward-looking statements. The words "estimate," "possible" and "seeking" and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information